NCT00840463View on ClinicalTrials.gov

Safety and Efficacy Trial to Treat Diastolic Heart Failure Using Ambrisentan

PHASE4TerminatedINTERVENTIONAL
Enrollment

4

Participants

Timeline

Start Date

January 31, 2009

Primary Completion Date

September 30, 2013

Study Completion Date

January 31, 2014

Conditions
Pulmonary HypertensionHeart Failure With Preserved Ejection Fraction
Interventions
DRUG

Ambrisentan

Subjects will be initiated at 2.5 mg per day and increased to 5mg daily in 2 weeks and then 10mg daily if clinically tolerated (edema is controlled and symptoms are stable).

OTHER

Placebo

Sugar pill

Trial Locations (1)

75390-8550

UT Southwestern Medical Center, Dallas

Sponsors

Collaborators (1)

Gilead Sciences
All Listed Sponsors
collaborator

Gilead Sciences

INDUSTRY

lead

University of Texas Southwestern Medical Center

OTHER